Genitourinary Cancers

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

Karim A. Touijer, MD, MPH, surgeon, Memorial Sloan Kettering Cancer Center, discusses the considering factors for surgical options for patients with renal cell carcinoma (RCC).

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

James J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.

When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.

Cabozantinib demonstrated consistent benefits compared with everolimus for patients with advanced, pretreated renal cell carcinoma in a subgroup analysis of the phase III METEOR trial that explored MET expression.

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.

Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.

Toni K. Choueiri, MD, dives into the ongoing research with volitinib, the competing yet complementary roles of targeted agents and immunotherapy, and the most important steps to take with biomarker research in the field of renal cell carcinoma.

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.